NYSE:MYOV - Myovant Sciences Stock Price, Forecast & News

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Myovant Sciences Ltd (NYSE:MYOV) released its quarterly earnings results on Monday, February, 10th. The company reported ($0.96) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.16. View Myovant Sciences' Earnings History.

Myovant Sciences is scheduled to release their next quarterly earnings announcement on Friday, May 22nd 2020. View Earnings Estimates for Myovant Sciences.

7 brokers have issued 12-month target prices for Myovant Sciences' stock. Their forecasts range from $15.00 to $34.00. On average, they expect Myovant Sciences' share price to reach $24.20 in the next year. This suggests a possible upside of 112.7% from the stock's current price. View Analyst Price Targets for Myovant Sciences.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences.

News stories about MYOV stock have been trending extremely negative on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Myovant Sciences earned a coverage optimism score of -4.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Myovant Sciences.

Some companies that are related to Myovant Sciences include Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), HUTCHISON CHINA/S (HCM), PTC Therapeutics (PTCT), Zai Lab (ZLAB), SAGE Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Axsome Therapeutics (AXSM), Intercept Pharmaceuticals (ICPT) and Myokardia (MYOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Amarin (AMRN), Energy Transfer LP Unit (ET), Sorrento Therapeutics (SRNE), Revance Therapeutics (RVNC), Clovis Oncology (CLVS), Intra-Cellular Therapies (ITCI), Bellicum Pharmaceuticals (BLCM), Exelixis (EXEL), Fate Therapeutics (FATE) and Immunomedics (IMMU).

(MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Myovant Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (5.26%), Eventide Asset Management LLC (4.60%), Victory Capital Management Inc. (2.78%), Victory Capital Management Inc. (2.75%), Lord Abbett & CO. LLC (2.08%) and FMR LLC (0.73%). Company insiders that own Myovant Sciences stock include Andrew Lo, Ferreira Juan Camilo Arjona, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Kim Sablich, Mark Altmeyer, Matthew Lang, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Institutional Ownership Trends for Myovant Sciences.

MYOV stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Bank of New York Mellon Corp, Victory Capital Management Inc., Victory Capital Management Inc., Bank of America Corp DE, Platinum Investment Management Ltd., Virginia Retirement Systems ET AL and Tower Research Capital LLC TRC . Company insiders that have sold Myovant Sciences company stock in the last year include Frank Karbe, Kim Sablich and Matthew Lang. View Insider Buying and Selling for Myovant Sciences.

MYOV stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, FMR LLC, Connor Clark & Lunn Investment Management Ltd., Candriam Luxembourg S.C.A., Raymond James & Associates, Oxford Asset Management LLP, Parkman Healthcare Partners LLC and Janus Henderson Group PLC. Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Insider Buying and Selling for Myovant Sciences.

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MYOV stock can currently be purchased for approximately $11.38.

Myovant Sciences has a market capitalization of $1.02 billion. The company earns $-273,550,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe.View Additional Information About Myovant Sciences.

The official website for Myovant Sciences is http://www.myovant.com/.

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3347 or via email at [email protected]